NewsBenzingaBTIG reafirma su recomendación de compra sobre Bicara Therapeutics y mantiene un precio objetivo de 39 dólares. BTIG reafirma su recomendación de compra sobre Bicara Therapeutics y mantiene un precio objetivo de 39 dólares. Benzinga 2026.10.19 09:56 (GMT+0) Open on Benzinga Other news Wells Fargo Maintains Equal-Weight on PENN Entertainment, Lowers Price Target to $22 HC Wainwright & Co. Reiterates Buy on Rigel Pharmaceuticals, Maintains $85 Price Target Alphabet Stock Rises: What's Going On? $1000 Invested In Agilent Technologies 10 Years Ago Would Be Worth This Much Today Wells Fargo Maintains Equal-Weight on MGM Resorts International, Lowers Price Target to $29 Mark Cuban Says Your Health Insurance Is More Likely To Get You Fired Than Al — It Costs Your Boss $30K
Mark Cuban Says Your Health Insurance Is More Likely To Get You Fired Than Al — It Costs Your Boss $30K
